Pioneering Cancer Diagnostics with Next-Generation Rapid Testing Solutions

At OncoFirm Diagnostics, we are revolutionizing cancer diagnostics through cutting-edge Fluorescent Lateral Flow Tests (FLFTs) and traditional lateral flow assay (LFA) technologies, specializing in rapid test development for early cancer detection. Our proprietary diagnostic solutions utilize various antigens, with highly specific biomarkers linked to cancer progression, to provide accurate, fast, and accessible screening tools.

Our Mission

At OncoFirm Diagnostics, It’s Personal

At OncoFirm Diagnostics, cancer isn’t just a medical challenge—it’s deeply personal. Every single person here has been touched by it. A parent. A sibling. A best friend. A child. We’ve felt the fear in the waiting rooms, the quiet heartbreak of uncertainty, and the desperate hope for just a little more time.

That shared pain is what brought us together. And it’s what drives us every single day.

We’re not just scientists, engineers, and professionals—we’re daughters, sons, friends, and survivors. We’ve stood on both sides of the diagnosis. That’s why we made a promise: to do something that truly matters.

At OncoFirm, we are united in one mission—to give people the power to know early enough to fight back. Because we believe early detection is not just science—it’s hope. It’s time. It’s a second chance.

Our diagnostics aren’t just tests. They’re lifelines. They’re born from the deepest place of empathy and built with the highest precision, because we know what’s at stake. We know that catching cancer early can mean the difference between watching your child graduate or not, between celebrating another anniversary or saying goodbye too soon.

This isn’t just a job for us. It’s a stand. A promise. A movement.

Together, we’re turning pain into purpose—and science into something profoundly human.

Because at OncoFirm Diagnostics, we don’t just fight cancer. We fight for the ones we love.

We will empower doctors, hospitals, clinics, and diagnostic laboratories with highly sensitive and reliable rapid cancer tests, enabling early detection, improved patient outcomes, and personalized treatment pathways.

Our Technology

Fluorescent Lateral Flow Tests (FLFTs) and (LFA) Lateral Flow Assay (LFA) Platforms: Fluorescent lateral flow tests offer much higher sensitivity, provide quantitative capability, reduce false positives and negatives, and are ideal for detecting low-concentration analytes. Enables cost-effective, point-of-care testing with rapid results in minutes, eliminating the need for complex laboratory infrastructure. Using highly specific antigen biomarkers associated with multiple types of cancers, enhancing test sensitivity and early-stage cancer detection.

Non-Invasive & Scalable Solutions: Designed for oncology screening programs, hospital diagnostics, and research institutions focusing on cancer and infectious diseases.

Who We Serve?
Hospitals & Clinics – Streamlining cancer diagnostics for early intervention and treatment planning.
Doctors & Oncologists – Providing rapid and reliable screening tools to enhance patient care.
Diagnostic Laboratories – Delivering innovative assays for precise cancer biomarker detection.
Cancer Screening Programs – Supporting large-scale early detection initiatives to improve survival rates.
Oncology & Infectious Disease Research – Advancing biomarker research for new therapeutic discoveries.

Why Choose Us?
✅ Rapid Results: LFA-based tests provide results in under 15 minutes.
✅ Highly Sensitive & Specific: based assays enhance early-stage cancer detection.
✅ Easy-to-Use & Non-Invasive: Designed for point-of-care settings with minimal training required.
✅ Cost-Effective & Scalable: Ideal for large-scale screening programs and clinical applications.

At OncoFirm Diagnostics, we are committed to driving the future of cancer diagnostics with groundbreaking biomarker-based rapid testing. Our innovations empower healthcare providers with faster, more accurate, and accessible tools for early cancer detection, ensuring better patient outcomes and improved survival rates worldwide.

For partnerships and inquiries, contact us at: investor@oncofirmdiagnostics.com